查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017229

梅毒免疫檢測測定診斷市場：依產品類型、技術、檢體類型和最終用戶分類－2026-2032年全球市場預測

Syphilis Immunoassay Diagnostic Market by Product Type, Technology, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，梅毒免疫檢測測定診斷市場價值將達到 5.7843 億美元，到 2026 年將成長至 6.1181 億美元，到 2032 年將達到 8.6744 億美元，複合年成長率為 5.95%。

主要市場統計數據
基準年 2025 5.7843億美元
預計年份：2026年 6.1181億美元
預測年份 2032 8.6744億美元
複合年成長率 (%) 5.95%

對現代醫學實踐中影響梅毒免疫檢測測定診斷的臨床、技術和操作促進因素的演變進行了清晰而令人信服的闡述。

梅毒免疫檢測測定診斷在公共衛生監測、臨床決策和檢查室現代化之間起著至關重要的作用。測量技術的進步、篩檢建議的擴展以及對性行為感染預防公共衛生工作的重新重視，已將診斷流程從間歇性檢測轉變為在臨床機構和社區內開展的綜合性、持續性篩檢。因此，診斷相關人員正在重新審視籌資策略、檢查室流程和臨床醫生培訓計劃，以確保檢測的及時性、準確性和實用性。

技術創新、檢查室自動化以及對公共衛生優先事項的重新評估如何全面重塑梅毒免疫檢測檢測和服務提供。

梅毒免疫檢測檢測診斷領域正經歷著變革性的轉變，這主要得益於技術的成熟、操作的整合以及政策對性行為感染感染日益成長的關注。化學冷光和螢光免疫分析技術的創新提高了分析性能，使得早期檢測和更可靠地區分既往感染與性行為感染成為可能。同時，照護現場設備和半自動分析儀的普及分散了檢測能力，使診所、社區支持計畫和小規模檢查室能夠在不完全依賴中心實驗室的情況下及時提供檢測結果。

評估 2025 年美國關稅調整對診斷供應鏈、籌資策略和檢查室採購韌性的營運外溢效應。

美國將於2025年實施的關稅調整，為診斷供應鏈和採購團隊的營運規劃帶來了新的挑戰。關稅變化影響了進口組件和成品檢測套組的單位成本，進而影響試劑和設備的採購決策，並改變了公立和私立檢測實驗室的庫存策略。為此，採購經理們正在審查與供應商的契約，協商更長期的協議以規避價格波動風險，並探索建立雙源採購機制以確保供應的連續性。

我們按產品、技術、檢體和最終用戶進行細分，以確定整個診斷環境中的採購因素、平台適用性和部署優先順序。

在梅毒免疫檢測領域，細緻的細分觀點對於理解其應用模式、採購因素和產品開發重點至關重要。根據產品類型，相關人員將產品分為「儀器」、「試劑盒」和「軟體」三類。儀器又細分為“全自動分析儀”、“照護現場（POC​​）設備”和“半全自動分析儀”，而試劑盒則細分為“品管試劑盒”、“即用型（RTU）試劑盒”和“試劑組”。這些分類指南資本投資規劃。全自動分析儀通常安裝在高通量檢查室中，而即時檢測設備則支援在診所和社區醫療機構進行分散式篩檢。即用型試劑盒透過最大限度地簡化製備過程來支援分散式檢查，而試劑組和品管試劑盒在品質保證計劃中仍然發揮核心作用。

影響全球採購選擇、監管環境和分銷策略的區域診斷環境和實施實踐。

區域趨勢影響梅毒免疫檢測測定診斷的需求、監管管道和分銷策略。在美洲，臨床篩檢重點、現有檢查室基礎設施和支付機制影響自動化分析儀和分散式檢查計劃的採用，這些計劃旨在擴大服務不足社區的檢測覆蓋範圍。區域法規結構和報銷模式推動新檢測方法的商業化進程，並塑造製造商與公共衛生計畫之間合作的機會。

梅毒免疫檢測測定診斷領域的競爭趨勢和供應商策略：強調平台合作、品質系統和服務主導差異化的重要性

梅毒免疫檢測測定診斷領域的競爭格局呈現出大型多元化診斷公司和專業創新企業並存的局面。成熟的體外診斷試劑生產商持續投資於平台相容性、檢測特異性和與實驗室資訊系統的整合，而專注於照護現場的便捷性、快速出結果和簡化試劑盒規格的公司則致力於提升檢測效率。實驗室設備供應商和試劑開發商之間的策略合作日益普遍，旨在提供整合解決方案，降低檢查室和診所採用這些方案的門檻。此外，契約製造和專業試劑供應商在確保關鍵檢測組件的品質穩定性和供應連續性方面發揮著至關重要的作用。

為製造商和檢查室管理人員提供可操作的策略重點，以增強梅毒免疫檢測的韌性，加快其應用，並提高其臨床效用。

產業領導者應採取積極主動的方式，在創新投資與務實的供應鏈和商業規劃之間取得平衡。優先考慮與實驗室資訊系統的互通性和無縫整合，將提高免疫檢測結果的臨床效用，並支援下游監測和報告。同時，製造商應擴展靈活的產品組合，以適應集中式檢查室處理能力和分散式即時篩檢（POC​​）的需求，從而在不影響分析完整性的前提下，實現廣泛的應用。

我們透過透明、多方面的研究途徑提供可操作的診斷信息，該方法結合了相關利益者訪談、監管分析和技術審查。

本研究整合了對實驗室管理人員、採購負責人、臨床用戶和行業高管的訪談所得出的見解，並輔以對監管指南、同行評審文獻和製造商技術文件的二次分析。主要研究著重於了解實際操作情況、採購決策者以及設備和檢測方法的實際應用經驗，而二級資訊來源提供了有關技術性能特徵、監管路徑和實施案例的背景資訊。

將梅毒檢測診斷創新轉化為更便捷的檢測、更高的可靠性和更大的公共衛生影響的關鍵見解和策略挑戰。

總之，梅毒免疫檢測檢測診斷領域正處於轉折點，技術進步、營運現代化和政策關注的交匯正在重塑檢測方式。儘管檢測技術的改進和分散式檢查的普及提高了診斷的可及性並縮短了診斷時間，但供應鍊和監管方面的考慮正在影響產品的開發、生產和採購方式。相關人員，將更有能力將診斷能力轉化為可衡量的公共衛生和臨床成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 梅毒免疫檢測測定診斷市場：依產品類型分類

  • 裝置
    • 全自動分析儀
    • 即時檢測設備
    • 半自動分析儀
  • 成套工具
    • 控制套件
    • 即用型套件
    • 試劑組
  • 軟體

第9章：梅毒免疫檢測測定診斷市場：依技術分類

  • 化學冷光免疫檢測
  • 酵素免疫分析法
  • 螢光免疫分析

第10章：以檢體類型分類的梅毒免疫檢測測定診斷市場

  • 血清/血漿
  • 全血

第11章 梅毒免疫檢測測定診斷市場：依最終用戶分類

  • 血庫
  • 診所
  • 測試機構
  • 醫院

第12章 梅毒免疫檢測測定診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 梅毒免疫檢測診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 梅毒免疫檢測測定診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國梅毒免疫檢測測定診斷市場

第16章：中國梅毒免疫檢測檢測診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Ortho Clinical Diagnostics, LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
Product Code: MRR-036CEF508599

The Syphilis Immunoassay Diagnostic Market was valued at USD 578.43 million in 2025 and is projected to grow to USD 611.81 million in 2026, with a CAGR of 5.95%, reaching USD 867.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 578.43 million
Estimated Year [2026] USD 611.81 million
Forecast Year [2032] USD 867.44 million
CAGR (%) 5.95%

A clear and compelling orientation to the evolving clinical, technological, and operational drivers shaping syphilis immunoassay diagnostics in contemporary healthcare settings

Syphilis immunoassay diagnostics occupy a critical intersection of public health surveillance, clinical decision-making, and laboratory modernization. Advances in assay technologies, expanded screening recommendations, and renewed public health emphasis on sexually transmitted infection control have elevated diagnostic workflows from episodic testing to sustained screening integrated across clinical and community settings. As a result, diagnostic stakeholders are recalibrating procurement strategies, laboratory processes, and clinician education programs to ensure testing is timely, accurate, and actionable.

Over the past several years, diagnostic providers have moved toward consolidated testing pathways that prioritize sensitivity and specificity while reducing time-to-result and hands-on operator time. This shift is evident in the uptake of automated platforms, the refinement of kit formats, and the broader integration of immunoassay outputs into electronic health records and surveillance systems. Looking ahead, resilience of supply chains, regulatory alignment, and interoperability of diagnostic data will increasingly determine how effectively syphilis testing supports prevention, treatment initiation, and population-level control efforts.

How technological innovation, laboratory automation, and renewed public health priorities are collectively reshaping syphilis immunoassay testing and service delivery

The landscape for syphilis immunoassay diagnostics is undergoing transformative shifts driven by technological maturation, operational consolidation, and heightened policy focus on sexually transmitted infections. Innovations in chemiluminescence and fluorescence immunoassay technologies have improved analytical performance, enabling earlier detection and more reliable differentiation between past and active infections. Concurrently, the proliferation of point-of-care devices and semi-automated analyzers is decentralizing testing capacity, allowing clinics, community outreach programs, and smaller laboratories to deliver timely results without full reliance on centralized reference labs.

Operationally, laboratories are prioritizing automation and workflow integration to reduce manual handling, lower error rates, and increase throughput. This trend is reinforced by health systems pursuing diagnostic stewardship-optimizing test ordering and result interpretation to improve clinical utility. At the policy level, renewed public health investment in STI screening programs and clearer clinical guidelines are expanding screening penetrance. Taken together, these shifts are creating a more responsive diagnostic ecosystem where performance, speed, and ease of use are paramount, and where strategic alignment across manufacturers, laboratories, and public health agencies will determine adoption trajectories.

Assessing the operational ripple effects of United States tariff adjustments in 2025 on diagnostic supply chains, sourcing strategies, and laboratory procurement resilience

The introduction of tariff adjustments in the United States in 2025 has introduced a new dimension of operational planning for diagnostic supply chains and procurement teams. Tariff changes affect the unit cost of imported components and finished assay kits, influence sourcing decisions for reagents and instruments, and alter inventory strategies across both commercial and public laboratories. In response, procurement leaders are reassessing supplier contracts, negotiating longer-term terms to hedge price volatility, and exploring dual-sourcing arrangements to protect continuity of supply.

Beyond immediate cost considerations, tariffs are accelerating conversations about nearshoring manufacturing and expanding domestic capacity for critical assay components. Manufacturers are evaluating the trade-offs between relocated production and the capital and regulatory investments required to establish compliant assembly and reagent production within domestic jurisdictions. For clinical laboratories and health systems, the practical implications include extended lead times for some imported instruments, a greater emphasis on inventory visibility, and a need for flexible procurement frameworks that can accommodate price pass-through while preserving access to essential diagnostics. These dynamics underscore the importance of proactive supply chain analytics and cross-functional coordination among procurement, clinical leadership, and manufacturer partners.

Deconstructing product, technology, sample, and end-user segmentations to reveal procurement drivers, platform fit, and deployment priorities across diagnostic settings

A granular segmentation view is essential for understanding adoption patterns, procurement drivers, and product development priorities across the syphilis immunoassay space. Based on Product Type, stakeholders differentiate offerings into Instruments, Kits, and Software, with Instruments further categorized as Automated Analyzer, Point Of Care Device, and Semi-Automated Analyzer, and Kits disaggregated into Control Kits, Ready-To-Use Kits, and Reagent Kits. These distinctions inform capital planning, with automated analyzers often anchored in high-throughput laboratories while point-of-care devices enable distributed screening in clinics and outreach settings. Ready-to-use kits support decentralized testing by minimizing preparation complexity, whereas reagent kits and control kits remain central to quality assurance programs.

Based on Technology, testing modalities such as Chemiluminescence Immunoassay, Enzyme-Linked Immunosorbent Assay, and Fluorescence Immunoassay drive differences in analytical sensitivity, workflow complexity, and platform compatibility. The choice of technology influences not only diagnostic performance but also laboratory staffing, instrument footprint, and integration requirements. Based on Sample Type, distinctions between Serum Plasma and Whole Blood specimen handling affect pre-analytical workflows, collection site logistics, and the feasibility of point-of-care screening in community and remote settings. Finally, based on End User, the landscape spans Blood Banks, Clinics, Diagnostic Laboratories, and Hospitals, each with distinct procurement cycles, quality systems, and decision criteria. Understanding these layered segmentations enables manufacturers and providers to tailor product design, regulatory strategies, and commercial approaches to the operational realities of their target end users.

Regional diagnostic landscapes and deployment realities shaping procurement choices, regulatory approaches, and distribution strategies across global territories

Regional dynamics shape demand profiles, regulatory pathways, and distribution strategies for syphilis immunoassay diagnostics. In the Americas, clinical screening priorities, established laboratory infrastructure, and payer mechanisms influence the adoption of automated analyzers as well as decentralized testing initiatives that aim to broaden access in underserved communities. The region's regulatory frameworks and reimbursement models drive the commercialization timelines for newer assay formats and shape collaboration opportunities between manufacturers and public health programs.

Europe, Middle East & Africa present a heterogeneous set of challenges and opportunities, where advanced diagnostic networks in some markets coexist with limited laboratory capacity in others. This diversity necessitates flexible product portfolios that can span high-throughput central labs to robust, low-maintenance point-of-care systems suitable for resource-constrained environments. Meanwhile, Asia-Pacific is characterized by rapid modernization of laboratory infrastructure, strong domestic manufacturing capabilities in several countries, and expanding public health screening initiatives. Across all regions, distribution partnerships, local regulatory compliance, and the ability to offer training and technical support are decisive factors that influence uptake and long-term utilization of diagnostic solutions.

Competitive dynamics and supplier strategies in syphilis immunoassay diagnostics demonstrating the importance of platform partnerships, quality systems, and service-driven differentiation

The competitive environment in syphilis immunoassay diagnostics reflects a blend of large, diversified diagnostics firms and specialized innovators. Established in-vitro diagnostics manufacturers continue to invest in platform compatibility, assay specificity, and integration with laboratory information systems, while niche companies focus on point-of-care convenience, rapid turnaround, and simplified kit formats. Strategic partnerships between instrument vendors and reagent developers are increasingly common, aiming to offer bundled solutions that reduce implementation friction for laboratories and clinics. In addition, contract manufacturers and specialized reagent suppliers play a pivotal role in ensuring consistent quality and supply continuity for core assay components.

For purchasers and partners, evaluation criteria often prioritize proven analytical performance, regulatory clearances in target geographies, post-market support capabilities, and a demonstrated track record on quality systems. Companies that combine robust technical documentation, accessible service networks, and flexible commercial terms are better positioned to meet the diverse needs of hospitals, diagnostic laboratories, clinics, and blood banks. As competition intensifies, differentiation increasingly hinges on end-to-end service models that extend beyond the instrument or kit to encompass training, maintenance, and data interoperability services.

Actionable strategic priorities for manufacturers and laboratory leaders to strengthen resilience, accelerate adoption, and enhance clinical utility of syphilis immunoassays

Industry leaders should adopt a proactive posture that balances innovation investment with pragmatic supply chain and commercial planning. Prioritizing interoperability and seamless integration with laboratory information systems will enhance the clinical utility of immunoassay results and support downstream surveillance and reporting. Simultaneously, manufacturers should expand flexible product configurations that address both centralized laboratory throughput and decentralized point-of-care screening, enabling broad access without sacrificing analytical integrity.

Leaders must also institute resilient procurement and manufacturing strategies that mitigate the impact of trade policy fluctuations. This includes diversifying supplier bases, assessing nearshoring options where feasible, and implementing inventory analytics to reduce stockouts. On the commercial front, targeted engagement with public health programs and care networks can accelerate adoption by aligning product offerings with screening guidelines and reimbursement frameworks. Finally, investing in clinician and laboratory education will enhance appropriate test utilization and result interpretation, thereby maximizing the clinical value of syphilis immunoassay diagnostics.

A transparent multi-source research approach combining stakeholder interviews, regulatory analysis, and technical review to deliver actionable diagnostic intelligence

This research synthesizes insights from primary interviews with laboratory directors, procurement officers, clinical users, and industry executives, complemented by secondary analysis of regulatory guidance, peer-reviewed literature, and manufacturer technical documentation. Primary engagement focused on capturing operational realities, procurement decision drivers, and real-world experiences with instruments and assay formats, while secondary sources provided context on technology performance characteristics, regulatory pathways, and implementation case studies.

Analytic methods included qualitative thematic analysis of stakeholder interviews, cross-comparison of product specifications and regulatory clearances, and scenario mapping of supply chain impacts. Wherever applicable, findings were triangulated across multiple information sources to validate themes and identify divergences between clinical practice and manufacturer claims. Confidentiality protocols were observed for all primary contributors, and the research approach emphasized transparency in assumptions and limitations to ensure the findings are actionable for decision-makers across industry and healthcare settings.

Key takeaways and strategic imperatives to convert diagnostic innovation into improved access, reliability, and public health impact for syphilis testing

In conclusion, the syphilis immunoassay diagnostic arena is at an inflection point where technological advances, operational modernization, and policy attention converge to reshape testing pathways. Improved assay technologies and the expansion of decentralized testing are enhancing access and shortening time-to-diagnosis, while supply chain and regulatory considerations are influencing how products are developed, manufactured, and procured. Stakeholders who align product strategies with end-user workflows, invest in integration and support, and build supply chain resilience will be best positioned to translate diagnostic capability into measurable public health and clinical outcomes.

Sustained progress will require collaboration across manufacturers, clinical laboratories, public health agencies, and procurement bodies to ensure that advances in assay performance are matched by practical implementation support. By focusing on interoperability, quality assurance, and accessible deployment models, the diagnostic community can strengthen syphilis screening programs and improve care pathways for affected populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Syphilis Immunoassay Diagnostic Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Automated Analyzer
    • 8.1.2. Point Of Care Device
    • 8.1.3. Semi-Automated Analyzer
  • 8.2. Kits
    • 8.2.1. Control Kits
    • 8.2.2. Ready-To-Use Kits
    • 8.2.3. Reagent Kits
  • 8.3. Software

9. Syphilis Immunoassay Diagnostic Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme-Linked Immunosorbent Assay
  • 9.3. Fluorescence Immunoassay

10. Syphilis Immunoassay Diagnostic Market, by Sample Type

  • 10.1. Serum Plasma
  • 10.2. Whole Blood

11. Syphilis Immunoassay Diagnostic Market, by End User

  • 11.1. Blood Banks
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals

12. Syphilis Immunoassay Diagnostic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Syphilis Immunoassay Diagnostic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Syphilis Immunoassay Diagnostic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Syphilis Immunoassay Diagnostic Market

16. China Syphilis Immunoassay Diagnostic Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Beckman Coulter, Inc.
  • 17.7. Becton Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. bioMerieux SA
  • 17.10. bioMerieux SA
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Ortho Clinical Diagnostics, LLC
  • 17.13. Siemens Healthineers AG
  • 17.14. Thermo Fisher Scientific Inc.
  • 17.15. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY AUTOMATED ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY AUTOMATED ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY AUTOMATED ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY POINT OF CARE DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY POINT OF CARE DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY POINT OF CARE DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SEMI-AUTOMATED ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SEMI-AUTOMATED ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SEMI-AUTOMATED ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CONTROL KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CONTROL KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CONTROL KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY READY-TO-USE KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY READY-TO-USE KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY READY-TO-USE KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SERUM PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SERUM PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SERUM PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 131. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 152. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 159. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY KITS, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)